Scars Pipeline Insight

DelveInsight’s, “Scars - Pipeline Insight, 2025” report provides comprehensive insights about 7+ companies and 10+ pipeline drugs in Scars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Scars: Understanding

Scars: Overview

Scars represent the natural end point of the wound healing process, replacing normal skin architecture with fibrous connective tissue. Healing occurs through overlapping phases of debridement, granulation, and re-epithelialization, followed by a prolonged maturation and remodeling stage, which may continue for up to two years. The resulting scar may be stable, as seen with simple surgical wounds, or pathological, as in hypertrophic or keloid scars. Pathological scars arise from an excessive fibroblast and myofibroblast response, leading to disorganized collagen deposition and altered skin texture and function. Because of their visibility and persistence, scars can have both physical and psychological impacts on patients.

The clinical manifestations of scars vary depending on type and location. Many scars are asymptomatic but can present as discolored, raised, or depressed lesions. Pathological scars are more likely to cause problems: itching, pain, tightness, and functional limitations are common, especially when scars form over joints, leading to contractures. Patients may also experience emotional distress due to changes in appearance. The PMC review highlights that nearly 100 million people each year develop scars from surgical or traumatic wounds, with around 15% progressing to hypertrophic or keloid scars. These scars can cause persistent symptoms such as pruritus, tenderness, restricted mobility, and even psychological trauma.

Scars can be classified into several types. Contracture scars typically occur in burn injuries or graft sites and may severely restrict movement across joints. Extended or enlarged scars are often pale and symptom-free, mainly posing cosmetic concerns, with stretch marks being a common example. Atrophic scars, seen after acne or chickenpox, present as sunken depressions due to tissue loss. Hypertrophic scars are raised, red, and inflamed but remain confined to the wound margin; they may cause itching or pain and often regress within two years. In contrast, keloid scars extend beyond the original wound into healthy tissue and do not regress, with high recurrence rates after excision. The PMC article further refines this classification into immature scars (red, raised, active) that may evolve into mature scars (flat and skin-colored) or persist as pathological variants.

The formation of scars is a dynamic biological process involving cellular and molecular mechanisms of wound repair. In normal healing, fibroblasts produce extracellular matrix (ECM) proteins, including collagen, which are later remodeled during the maturation phase. Pathological scarring, however, results from excessive fibroblast and myofibroblast activity, leading to persistent inflammation, abnormal collagen cross-linking, and thickened tissue. The PMC article emphasizes the role of fibroblast heterogeneity, with different subpopulations contributing uniquely to hypertrophic, keloid, or atrophic scars. Mechanical stress, prolonged inflammatory signaling, and imbalanced ECM remodeling further drive the abnormal healing response. This explains why hypertrophic and keloid scars tend to be more vascular, raised, and symptomatic compared to normal scars.

Managing scars remains a clinical challenge, especially in the case of pathological scars. Hypertrophic scars often improve spontaneously but may require intervention if symptomatic. Treatments include silicone gel sheets, pressure therapy, and intralesional corticosteroids, which reduce inflammation and collagen production. Keloid scars, however, are more resistant to treatment and frequently recur after surgical excision, necessitating combined approaches such as surgery with steroid injections, cryotherapy, or laser therapy. The PMC review also discusses emerging therapies targeting fibroblast signaling pathways, growth factor modulation, and extracellular matrix remodeling, which may offer more effective and tailored options in the future. Overall, treatment strategies range from non-invasive topical applications to invasive surgical and pharmacologic interventions, depending on scar type and severity.

 

"Scars- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scars pipeline landscape is provided which includes the disease overview and Scars treatment guidelines. The assessment part of the report embraces, in depth Scars commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scars collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Scars R&D. The therapies under development are focused on novel approaches to treat/improve Scars.

 

Scars Emerging Drugs Chapters

This segment of the Scars report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Scars Emerging Drugs

• OLX101A : Olix Pharmaceuticals

OLX101A is an investigational intradermal injection being developed for the treatment of hypertrophic scars or keloids caused by damage to the dermis and excessive production of collagen fibers. Unlike traditional surgical approaches that do not influence scar formation pathways, OLX101 specifically blocks collagen synthesis by targeting CTGF mRNA. CTGF plays a key role in fibrotic disorders by stimulating the synthesis of extracellular matrix (ECM) proteins such as collagen. An abnormal wound healing response, marked by excessive collagen deposition from CTGF overexpression, often results in hypertrophic scars or keloids. Currently, the drug is in Phase II stage of its clinical study for the treatment of hypertrophic scars or keloids.

 

• AGLE-102 : Aegle Therapeutics

AGLE-102 is an investigational therapy formulated from native extracellular vesicles (EVs) derived from allogeneic mesenchymal stem cells (MSCs). Designed as a topical treatment for severe dermatological disorders, AGLE-102 harnesses the natural repair and regenerative properties of MSCs. The EVs serve as carriers of key biomolecules that mediate the therapeutic actions of MSCs, enabling tissue repair and regeneration. Currently, the drug is in Phase I/II stage of its clinical study for the treatment of Burns.

Further product details are provided in the report……..

 

Scars: Therapeutic Assessment

This segment of the report provides insights about the different Scars drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Scars

• There are approx. 7+ key companies which are developing the therapies for Scars. The companies which have their Scars drug candidates in the most advanced stage, i.e. Phase II include, Olix Pharmaceuticals.

 

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Scars pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Scars: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Scars therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scars drugs.

 

Scars Report Insights

• Scars Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Scars Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Scars drugs?
• How many Scars drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scars?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Scars therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Scars and their status?
• What are the key designations that have been granted to the emerging drugs?